Obesity

• EMA label_change · 2025-03-28
  EMA concludes review of weight management medicine Mysimba

  The EMA concluded its review of Mysimba, confirming that benefits continue to outweigh risks and noting new risk minimisation measures and a…

• FDA label_change · 2024-12-20
  FDA Approved: ZEPBOUND — Supplemental Application (Eli Lilly and Company)

  FDA approves a supplemental application for ZEPBOUND (tirzepatide) from Eli Lilly to update the drug's labeling related to weight management…

• FDA label_change · 2021-04-14
  FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)

  FDA approved a supplemental application for Contrave Extended-Release (naltrexone hydrochloride and bupropion hydrochloride) from Nalpropion…

• FDA label_change · 2019-06-17
  FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  FDA approves a supplemental application for liraglutide from Teva Pharmaceuticals USA, Inc., resulting in changes to the product labeling.

• FDA label_change · 2015-03-27
  FDA Approved: SAXENDA — Supplemental Application (Novo Nordisk)

  The FDA has approved a supplemental application for Saxenda (liraglutide) by Novo Nordisk, likely resulting in changes to its labeling.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA label_change · 2013-04-16
  FDA Approved: LIRAGLUTIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  The FDA approved a supplemental application for liraglutide from Teva Pharmaceuticals USA, Inc., resulting in changes to the product labelin…